Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

PURPOSE: Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EGFR-TKIs and had acquired a T790M mutation. The ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Yuxin, Hao, Xuezhi, Xing, Puyuan, Hu, Xingsheng, Wang, Yan, Li, Teng, Zhang, Jinyao, Xu, Ziyi, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382655/
https://www.ncbi.nlm.nih.gov/pubmed/32385709
http://dx.doi.org/10.1007/s00432-020-03239-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382655/
https://www.ncbi.nlm.nih.gov/pubmed/32385709
http://dx.doi.org/10.1007/s00432-020-03239-1

Ejemplares similares